| Outcome Measures: |
Primary: To evaluate the pharmacokinetics of warfarin after a single dose when administered alone and in combination with AZD1656 at steady state by assessment of AUC and Cmax of both enantiomers of warfarin (S- and R-warfarin)., Serial PK blood samples will be taken on days 4-10 during the treatment periods | Secondary: To evaluate the anticoagulant activity of warfarin upon co-administration with AZD1656 by assessment of prothrombin time (PT) and international normalised ratio (INR)., Serial blood samples for warfarin PD measurements will be taken on days 4-10 during the treatment periods|To evaluate the safety of AZD1656 in combination with warfarin by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables (including 7-point glucose), physical examination and adverse events, Safety assessments will be monitored throughout the study, from screening visit until follow up visit.|To describe the pharmacokinetics of AZD1656 and its metabolite during concomitant warfarin administration by assessment of AUC0-24, Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only)., Serial PK blood samples will be taken on days 4-10 during the treatment periods
|
